Blurbs

Needham Thinks Autolus Therapeutics’ Stock is Going to Recover

In a report released today, Gil Blum from Needham maintained a Buy rating on Autolus Therapeutics (AUTLResearch Report), with a price target of $13.00. The company’s shares closed last Monday at $2.28, close to its 52-week low of $2.20.

According to TipRanks.com, Blum is ranked 0 out of 5 stars with an average return of -36.2% and a 18.6% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Rocket Pharmaceuticals, and Aeglea Biotherapeutics.

Currently, the analyst consensus on Autolus Therapeutics is a Strong Buy with an average price target of $14.00, a 444.7% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $18.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Autolus Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $37.06 million. In comparison, last year the company had a GAAP net loss of $33.27 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm’s portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.

Read More on AUTL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
Videos

Latest News Feed